Literature DB >> 20581741

Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency.

Nahid Waleh1, Ryan Hodnick, Nami Jhaveri, Suzanne McConaghy, John Dagle, Steven Seidner, Donald McCurnin, Jeffrey C Murray, Robin Ohls, Ronald I Clyman.   

Abstract

Three independent risk factors (immature gestation, absence of antenatal glucocorticoid exposure, and presence of the rs2817399(A) allele of the gene TFAP2B) are associated with patent ductus arteriosus (PDAs) that fail to close during prostaglandin inhibition. We hypothesized that these three factors may affect a common set of genes that increase the risk of persistent PDA after birth. We studied baboon ductus from term, preterm, and glucocorticoid-treated preterm fetuses and found that both immature gestation and absence of antenatal glucocorticoid exposure decreased RNA expression of calcium- and potassium-channel genes involved in oxygen-induced constriction, and phosphodiesterase genes (that modulate cAMP/cGMP signaling). Ductus obtained from second trimester human pregnancies were genotyped for TFAP2B polymorphisms. When present, the rs2817399(A) allele also was associated with decreased expression of calcium- and potassium-channel genes. In contrast, alleles of two other TFAP2B polymorphisms, rs2817419(G) and rs2635727(T), which are not related to the incidence of PDA after birth, had no effect on RNA expression. In conclusion, three calcium- and potassium-channel genes (CACNA1G/ alpha1G, CACNB 2/CaL-beta2, and KCNA2/ Kv1.2) were similarly affected by each of the PDA risk factors. We speculate that these channels may play a significant role in closing the preterm ductus during prostaglandin inhibition and may be potential targets for future pharmacologic manipulations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581741      PMCID: PMC2940964          DOI: 10.1203/PDR.0b013e3181ed8609

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  41 in total

1.  Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation.

Authors:  F Zhao; C G Weismann; M Satoda; M E Pierpont; E Sweeney; E M Thompson; B D Gelb
Journal:  Am J Hum Genet       Date:  2001-08-14       Impact factor: 11.025

2.  Glucocorticoids inhibit the expression of calcium-dependent potassium channels in vascular smooth muscle.

Authors:  A S Brem; R B Bina; S Mehta; J Marshall
Journal:  Mol Genet Metab       Date:  1999-05       Impact factor: 4.797

3.  Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta.

Authors:  M Moser; A Pscherer; C Roth; J Becker; G Mücher; K Zerres; C Dixkens; J Weis; L Guay-Woodford; R Buettner; R Fässler
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

4.  Comparative analysis of AP-2 alpha and AP-2 beta gene expression during murine embryogenesis.

Authors:  M Moser; J Rüschoff; R Buettner
Journal:  Dev Dyn       Date:  1997-01       Impact factor: 3.780

5.  Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle.

Authors:  L Smith; J B Smith
Journal:  J Biol Chem       Date:  1994-11-04       Impact factor: 5.157

6.  Glucocorticoids increase Ca2+ uptake and [3H]dihydropyridine binding in A7r5 vascular smooth muscle cells.

Authors:  T Hayashi; T Nakai; S Miyabo
Journal:  Am J Physiol       Date:  1991-07

7.  Prostaglandin E2--mediated relaxation of the ductus arteriosus: effects of gestational age on g protein-coupled receptor expression, signaling, and vasomotor control.

Authors:  Nahid Waleh; Hiroki Kajino; Anne Marilise Marrache; David Ginzinger; Christine Roman; Steven R Seidner; Timothy J M Moss; Jean-Claude Fouron; Alejandro Vazquez-Tello; Sylvain Chemtob; Ronald I Clyman
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

8.  Dexamethasone modulates the expression of endothelin-1 and -A receptors in A7r5 vascular smooth muscle cells.

Authors:  Y Koshino; T Hayashi; S Matsukawa; K Asazuma; K Eguchi; H Kato; T Nakai; I Miyamori
Journal:  J Cardiovasc Pharmacol       Date:  1998-10       Impact factor: 3.105

9.  Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo.

Authors:  L Kornel; A V Prancan; N Kanamarlapudi; J Hynes; E Kuzianik
Journal:  Endocr Res       Date:  1995 Feb-May       Impact factor: 1.720

10.  Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates.

Authors:  Andras Treszl; Miklos Szabo; Gyorgy Dunai; Andras Nobilis; Istvan Kocsis; Tamas Machay; Tivadar Tulassay; Barna Vasarhelyi
Journal:  Pediatr Res       Date:  2003-08-06       Impact factor: 3.756

View more
  17 in total

1.  Genetic variants associated with patent ductus arteriosus in extremely preterm infants.

Authors:  John M Dagle; Kelli K Ryckman; Cassandra N Spracklen; Allison M Momany; C Michael Cotten; Joshua Levy; Grier P Page; Edward F Bell; Waldemar A Carlo; Seetha Shankaran; Ronald N Goldberg; Richard A Ehrenkranz; Jon E Tyson; Barbara J Stoll; Jeffrey C Murray
Journal:  J Perinatol       Date:  2018-12-05       Impact factor: 2.521

2.  Familial nonsyndromic patent ductus arteriosus caused by mutations in TFAP2B.

Authors:  Yi-Wei Chen; Wu Zhao; Zhi-Fang Zhang; Qihua Fu; Jie Shen; Zhen Zhang; Wei Ji; Jian Wang; Fen Li
Journal:  Pediatr Cardiol       Date:  2011-06-04       Impact factor: 1.655

3.  Predictors of successful closure of patent ductus arteriosus with indomethacin.

Authors:  M F Ahamed; P Verma; S Lee; M Vega; D Wang; M Kim; M Fuloria
Journal:  J Perinatol       Date:  2015-04-09       Impact factor: 2.521

4.  Response to Coceani et al.

Authors:  Ravi Goyal; Ronald I Clyman
Journal:  Pediatr Res       Date:  2017-06-14       Impact factor: 3.756

Review 5.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

6.  Antenatal calcium channel blocker exposure and subsequent patent ductus arteriosus in extremely low-birth-weight infants.

Authors:  Jennifer McGuirl; Bonnie Arzuaga; Ben H Lee
Journal:  Pediatr Cardiol       Date:  2011-08-23       Impact factor: 1.655

Review 7.  Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.

Authors:  Yang Hu; Hongfang Jin; Yi Jiang; Junbao Du
Journal:  Pediatr Cardiol       Date:  2018-02-21       Impact factor: 1.655

8.  Relationship between circulating platelet counts and ductus arteriosus patency after indomethacin treatment.

Authors:  Nidhi A Shah; Nancy K Hills; Nahid Waleh; Donald McCurnin; Steven Seidner; Sylvain Chemtob; Ronald Clyman
Journal:  J Pediatr       Date:  2010-12-30       Impact factor: 4.406

Review 9.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

10.  Genetic Modifiers of Patent Ductus Arteriosus in Term Infants.

Authors:  Priti M Patel; Allison M Momany; Kendra L Schaa; Paul A Romitti; Charlotte Druschel; Margaret E Cooper; Mary L Marazita; Jeffrey C Murray; John M Dagle
Journal:  J Pediatr       Date:  2016-06-22       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.